XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Update

XOMA Royalty Corporation (NASDAQ:XOMA) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 1,051,282 shares, an increase of 27.4% from the January 15th total of 824,924 shares. Currently, 9.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 783,079 shares, the short-interest ratio is currently 1.3 days. Based on an average daily trading volume, of 783,079 shares, the short-interest ratio is currently 1.3 days. Currently, 9.1% of the shares of the stock are sold short.

XOMA Royalty Trading Up 1.9%

XOMA Royalty stock traded up $0.46 during midday trading on Tuesday, reaching $24.47. 100,125 shares of the stock traded hands, compared to its average volume of 619,020. The company has a current ratio of 3.91, a quick ratio of 3.91 and a debt-to-equity ratio of 1.07. The firm has a market cap of $302.94 million, a PE ratio of 33.07 and a beta of 0.86. The company has a 50-day simple moving average of $26.31 and a two-hundred day simple moving average of $31.15. XOMA Royalty has a 12-month low of $18.35 and a 12-month high of $39.92.

Insiders Place Their Bets

In other XOMA Royalty news, CEO Owen Hughes purchased 100,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The shares were purchased at an average cost of $25.05 per share, for a total transaction of $2,505,000.00. Following the completion of the transaction, the chief executive officer owned 102,000 shares of the company’s stock, valued at $2,555,100. The trade was a 5,000.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 7.20% of the company’s stock.

Institutional Investors Weigh In On XOMA Royalty

A number of hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. boosted its position in XOMA Royalty by 3,436.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 756 shares during the period. State of Alaska Department of Revenue purchased a new position in XOMA Royalty in the fourth quarter valued at $27,000. Tower Research Capital LLC TRC grew its stake in XOMA Royalty by 203.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,523 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in XOMA Royalty by 266.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,346 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in XOMA Royalty by 13.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 543 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently commented on XOMA shares. HC Wainwright cut their price target on XOMA Royalty from $104.00 to $97.00 and set a “buy” rating for the company in a report on Thursday, December 11th. Weiss Ratings reiterated a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. TD Cowen raised shares of XOMA Royalty to a “hold” rating in a report on Friday. Stifel Nicolaus set a $50.00 price objective on shares of XOMA Royalty in a research report on Friday, December 12th. Finally, UBS Group set a $76.00 target price on shares of XOMA Royalty in a report on Tuesday, December 9th. Three investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, XOMA Royalty presently has an average rating of “Moderate Buy” and an average price target of $60.60.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.